Which GLP‑1 receptor agonist is recommended for a patient with active esophageal and gastric ulcers?

GLP-1 Receptor Agonists Are NOT Recommended for Patients with Active Esophageal and Gastric Ulcers

No GLP-1 receptor agonist should be used in patients with active esophageal and gastric ulcers due to the drugs' effects on gastric emptying, increased gastroesophageal reflux, and potential worsening of upper GI pathology.

Primary Concern: Delayed Gastric Emptying and GERD Risk

All GLP-1 receptor agonists delay gastric emptying as a core mechanism of action 1, 2. This creates several problems for patients with active ulcers:

• Increased gastric retention leads to prolonged acid exposure to ulcerated tissue
• Enhanced gastroesophageal reflux worsens esophageal ulcer healing 3, 4, 5
• Delayed gastric emptying can increase risk of aspiration and complications 2

Evidence of GI Harm

Recent high-quality evidence demonstrates significant GI risks:

Short-acting GLP-1 RAs are particularly problematic 3:

• Increased risk of erosive reflux disease (HR 1.215)
• Higher rates of esophageal stricture (HR 1.284)
• Increased Barrett's esophagus without dysplasia (HR 1.372)
• Increased Barrett's with dysplasia (HR 1.505)

All GLP-1 RAs increase GERD risk 4, 5:

• Meta-analysis shows RR 2.19 for GERD compared to placebo 4
• Population study shows RR 1.27 for GERD vs SGLT-2 inhibitors 5

Esophageal motility abnormalities are directly associated with GLP-1 RA use 6, which would impair ulcer healing.

Clinical Algorithm for This Patient

Step 1: Discontinue any current GLP-1 RA immediately

• The delayed gastric emptying and increased reflux directly contradict ulcer healing
• Risk of complications outweighs any metabolic benefit

Step 2: Alternative diabetes management (if applicable)

• Use SGLT-2 inhibitors, DPP-4 inhibitors, or insulin instead
• These do not delay gastric emptying or worsen reflux

Step 3: Optimize ulcer healing

• High-dose proton pump inhibitors
• Treat H. pylori if present
• Avoid NSAIDs and other ulcerogenic agents

Step 4: Reassess after complete ulcer healing

• Only consider GLP-1 RA after documented endoscopic healing
• If restarted, prefer long-acting formulations (less GERD risk than short-acting) 3
• Monitor closely for recurrent symptoms

Critical Pitfalls to Avoid

Do not rationalize GLP-1 RA use based on:

• Cardiovascular benefits - these don't apply when active ulcers are present
• Weight loss goals - ulcer healing takes priority over weight management
• Glycemic control - other agents can achieve this without GI harm

Do not assume proton pump inhibitors will protect against GLP-1 RA effects:

• PPIs reduce acid but don't address delayed gastric emptying 2
• The mechanical effects of delayed emptying persist regardless of acid suppression

When GLP-1 RAs Might Be Reconsidered

Only after:

1. Complete endoscopic healing of all ulcers documented
2. At least 8-12 weeks of ulcer-free status
3. No ongoing GERD symptoms
4. Compelling indication (diabetes with cardiovascular disease or significant obesity)
5. Patient understands increased monitoring requirements

If restarted, long-acting formulations (semaglutide, dulaglutide, tirzepatide) are preferred over short-acting agents (liraglutide, lixisenatide, exenatide) as they cause less pronounced gastric emptying delay and lower GERD risk 3, 7.